TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1279-1290

  Alvero, Ayesha B ^a   Heaton, Andrew ^b,c   Lima, Eydis ^a   Pitruzzello, Mary ^a   Sumi, Natalia ^a   Yang Hartwich, Yang ^a   Cardenas, Carlos ^a   Steinmacher, Sahra ^a   Silasi, Dan Arin ^a   Brown, David ^b,c   Mor, Gil ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CanTx   (United States)

^c Novogen Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HERMES ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; PROTEIN C JUN; TRX E 002 1; UNCLASSIFIED DRUG; 4-(PARA-HYDROXYPHENYL)-7,4'-DIHYDROXY-3',5'-DIMETHOXY-8-METHYLISOFLAVAN; FLAVONOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; OVARIAN NEOPLASMS; PHOSPHORYLATION; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971539250     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0005     Document Type: Article

References (52)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: NCI; 2014. Available from: http://seer.cancer.gov/csr/1975-2012/.
3. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6.
4. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
5. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med 2007;58:267-84.
6. Hemmings C.The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 2010;42: 105-12.
7. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011;2011:941876.
8. Winquist RJ, Furey BF, Boucher DM. Cancer stem cells as the relevant biomass for drug discovery. Curr Opin Pharmacol 2010;10:385-90.
9. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009;8:158-66.
10. Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 2013;12:511-21.
11. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/ CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 2012;29:939-48.
12. Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol 2003;20:255-63.
13. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012;18:869-81.
14. Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, et al. NV-128,anovel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer 2009;115:3204-16.
15. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway. Cell Cycle 2011;10:2206-14.
16. Green JM, Alvero AB, Kohen F, Mor G. 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol Ther 2009;8:1747-53.
17. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med 2009;7:63.
18. Yao LH, Jiang YM, Shi J, Tomas-Barberan FA, Datta N, Singanusong R, et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr 2004;59:113-22.
19. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611-20.
20. Alvero AB, Rossi P, Brown D, Leizer A, Kelly M, Rutherford T, Husband A, Mor G. Phenoxodiol-A chemosensitizer in the midst of cancer chemoresistance. US Oncology 2008;4:39-41.
21. Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biol Ther 2007;6:612-7.
22. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006;106:599-608.
23. Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs 2011;22:719-31.
24. Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005;65:3364-73.
25. Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, et al. Antitumor activity of phenoxodiol: from bench to clinic. Future Oncol 2008;4:475-82.
26. Rutherford T, O'malley D, Makkenchery A, Baker L, Azodi M, Schwartz P, et al. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that resistant to second line chemotherapy. J Soc Gynecol Investig 2004;11:254.
27. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004;14:567-78.
28. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 2011;10: 1385-93.
29. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stemlike ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009;27:2405-13.
30. Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol 2012;67:256-65.
31. Alvero AB, Montagna MK, Sumi NJ, Joo WD, Graham E, Mor G. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget 2014;5:8703-15.
32. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013;32:39-49.
33. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010;29:3545-53.
34. Artymovich K, Appledorn DM. A multiplexed method for kinetic measurements of apoptosis and proliferation using live-content imaging. Methods Mol Biol 2015;1219:35-42.
35. Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B, et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013;2:751-62.
36. PizzoniaJ,HolmbergJ,OrtonS,AlveroA,ViteriO,McLaughlinW,etal. Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors. Am J Reprod Immunol 2012; 67:84-90.
37. Sumi NJ, Lima E, Pizzonia J, Orton SP, Craveiro V, Joo W, et al. Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence. J Vis Exp 2014:e51815.
38. Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, et al. Eradication of chemotherapy-resistant CD44+ human ovarian cancerstem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 2011;117:5519-28.
39. Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, et al. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci 2013;20:605-15.
40. Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011;2011:620523.
41. Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegen E, et al. Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS One 2013;8:e57329.
42. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008;27:6245-51.
43. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24-37.
44. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6.
45. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
46. Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B, et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013;2:751-62.
47. Bapat SA.Human ovarian cancer stem cells. Reproduction 2010; 140:33-41.
48. Al Mutairi NJ, Le T. Does modality of adjuvant chemotherapy after interval surgical debulking matter in epithelial ovarian cancer? An exploratory analysis. Int J Gynecol Cancer 2014;24:461-7.
49. Singer G, Oldt R, 3rd Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95: 484-6.
50. Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell 2011;2:889-98.
51. Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J 1997;16:1695-709.
52. Musti AM, Treier M, Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997;275: 400-2.